Valvular heart disease across specialties

LG Bryson
Consultant Physician and Cardiologist, South Tyneside District Hospital, Tyneside, England, UK

To investigate case reports suggesting that ergot-derived dopamine agonists, used to treat Parkinson’s disease, may increase the risk of cardiac valve regurgitation, the authors used a cohort of 11,417 subjects from the UKGPRD prescribed antiparkinsonian drugs. Thirty-one patients with newly diagnosed valve regurgitation were each matched with up to 25 controls from the cohort. Six cases were currently taking pergolide, six cases were currently taking cabergoline and 19 cases had had no exposure to dopamine agonists over the previous year. Cardiac valve regurgitation was increased among patients currently using pergolide (19% vs 4%) or cabergoline (19% vs 5%) but not in those using other dopamine agonists.

Echocardiograms were carried out on 155 patients taking dopamine agonists for Parkinson’s Disease (pergolide, 64; cabergoline, 49; and non-ergot-derived dopamine agonists, 42) and 90 controls to investigate a reported association of ergot-derived dopamine agonists with cardiac valvular disease.

Mitrval, Aortic and Tricuspid regurgitation judged echocardiographically moderate or severe (grade 3–4) was significantly more frequent in patients taking cabergoline (28-6%) or pergolide (23-4%) but not in patients taking non-ergot derived dopamine agonists (0%) compared to controls (5-6%). Patients treated with ergot-derived dopamine agonists with grade 3–4 regurgitation of any valve had received higher cumulative doses than those with grade 0–2 regurgitation (P values; pergolide 0-02, cabergoline 0-03). The endocardial abnormality is similar to that encountered in Carcinoid Syndrome and the postulated mechanism of valvular damage is stimulation of 5–hydroxytryptamine receptors of subtype 5–HT2B.

These two papers add compelling evidence that the dopamine agonists, pergolide and cabergoline, can be added to the list of drugs causing cardiac valve damage (drug valvulopathy). However, the implications go beyond merely adding two more drugs to a list.

First, how do such apparently diverse drugs cause cardiac valvulopathy? This is reviewed in an editorial accompanying the papers (Roth BL. Drugs and valvular heart disease. NEJM 2007; 356;6–9). The answer seems to be that these drugs have an affinity for 5–HT2B receptors which are plentiful on human cardiac valves. Activation of the 5–HT2B receptor leads to proliferation of valvular interstitial cells and eventually to fibrosis. One important implication of this is that doctors should avoid prescribing

TABLE 1 Potent 5–HT2B receptor agonists.
Valvular heart disease across specialties

potent 5–HT/2B receptor agonists (see Table 1), and another is that candidate drugs and their main metabolites should be tested for 5–HT/2B receptor activity to prevent problems with future drugs.

Second, the findings also emphasise the importance of general medical knowledge and a general clinical approach for all physicians, particularly when following up patients with chronic disease. It is only too easy for specialists in one field to confine their attention to that area, but here are drugs likely to be recommended by one specialist causing gradually developing serious problems in another specialist area.

Finally, one paper (Schade et al) illustrates the value of international co-operation. Researchers in Berlin and Montreal used the UKGPRD to identify this drug problem. May medicine remain an international endeavour!

Editor’s note

Correspondence related to these papers has asked whether low daily or cumulative doses of cabergoline and pergolide predispose to drug valvulopathy. The evidence that these drugs cause valvulopathy relates to patients taking higher drug doses (>3 mg/day for at least 6 months). Prolactin-secreting tumours are usually treated with cabergoline at lower doses (0·25–2·0 mg weekly); this may prove to be safe, but patients should be monitored with vigilance until the position is clarified.1


Conferencing & Events

The Royal College of Physicians of Edinburgh, located in Edinburgh city centre, has a unique blend of rooms providing perfect surroundings for your conference, meeting or event. The Victorian Great Hall, galleried New Library and the Georgian Cullen Suite are wonderful settings for dinners and receptions. The modern Conference Centre seats up to 300 people in raked seating and is complemented by breakout rooms seating from 10 to 150 people; a key pad voting system and video conferencing. The Centre is surrounded by dedicated exhibition and refreshments areas. Catering is provided by one of our panel of approved caterers.

The College provides a stunning setting for wedding and receptions and is licensed for both civil and religious ceremonies.

We can also offer a themed dinner in conjunction with Mercat Tours and Heritage Portfolio. Two actors bring to life some of the more macabre medical tales and introduce some of the College artefacts and books not normally on display.

Discounts are available for Fellows and for medical conferences and charities. For more information and for a quotation, please contact the Events Team on +44 (0)131 225 7324; email events@rcpe.ac.uk or visit the website at www.rcpe.ac.uk and choose the link to Conferencing and Events.